1. Buschke A: Ueber Sclerodermie. Bert Klin Wochenschr 39:955, 1902
2. Greenberg LM et al: Scleredema adultorum in children. Paediatrics 32:1044, 1963
3. Oikarinen A et al: Scleredema and paraproteinemia. Enhanced
collagen production and elevated type I procollagen messenger RNA level in fibroblasts grown from cultures from the fibrotic skin of a patient.
Arch Dermatol 123:226, 1987
4. Haapasaari KM et al: Increased
collagen propeptides in the skin of a scleredema patient but no change in re-epithelialisation rate.
Acta Derm Venereol 76:305, 1996
5. Kobayashi T et al: Diabetic scleredema: A case report and biochemical analysis for glycosaminoglycans. J Dermatol 24:100, 1997
6. Ohta A et al: Paraproteinemia in patients with scleredema: Clinical findings and serum effects on skin fibroblasts in vitro. J Am Acad Dermatol 16:96, 1987
7. Wright RA, Bernie H: Scleredema adultorum of Buschke with upper esophageal involvement. Am J Gastroenterol 77:9, 1982
8. Basarab T et al: Systemic involvement in scleredema of Buschke associated with IgG-kappa paraproteinaemia. Br J Dermatol 136:939, 1997
9. Janiga JJ et al: UVA-1 as a treatment for scleredema. Photodermatol Photoimmunol Photomed. 20:210, 2004
10. Eberlein-Konig B et al: Successful UVA1 phototherapy in a patient with scleredema adultorum. J Eur Acad Dermatol Venereol 19:203, 2005
11. Hager CM et al: Bath-PUVA therapy in three patients with scleredema adultorum. J Am Acad Dermatol 38:240, 1998
12. Montgomery H, Underwood LJ: Lichen myxedematosus; differentiation from cutaneous myxedemas or mucoid states. J Invest Dermatol 20:213, 1953
13. Gottron HA: Skleromyxodem (eine eigenartige euscheinungs-form von myxothesaurodermie). Arch Dermatol Syphil 199:71, 1954
14. Montgomery H: Diseases of metabolism. In: Dermatopathology, edited by Montgomery H. New York, Harper & Row, 1967, p. 830
15. Harper RA, Rispler J: Lichen myxedematosus serum stimulates skin fibroblast proliferation. Science 199:545, 1978
16. Yaron M et al: Lichen myxedematosus (scleromyxedema) serum stimulates hyaluronic acid and prostaglandin E production by human fibroblasts. J Rheumatol 12:171, 1985
17. Stetsenko GY et al: Unusual granulomatous variant of scleromyxedema. J Am Acad Dermatol 59:346, 2008
18. Feldman P et al: Scleromyxedema. A dramatic response to
melphalan.
Arch Dermatol 99:51, 1969
19. Harris RB et al: Treatment of scleromyxedema with
melphalan.
Arch Dermatol 115:295, 1979
20. Dinneen AM, Dicken CH: Scleromyxedema. J Am Acad Dermatol 33:37-43, 1995
21. Rayson D et al: Scleromyxedema: A complete response to
prednisone.
Mayo Clin Proc 74:481, 1999
22. Lister RK et al: Scleromyxedema: Response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol. 43:403, 2000
23. Caradonna S, Jacobe H:
Thalidomide as a potential treatment for scleromyxedema.
Arch Dermatol 140:277, 2004
24. Berkson M et al: Extracorporeal photochemotherapy: A potentially useful treatment for scleromyxedema. J Am Acad Dermatol 25:724, 1991
25. Tschen JA, Chang JR: Scleromyxedema: Treatment with interferon alfa. J Am Acad Dermatol 40:303, 1999
26. Farr PM, Ive FA: PUVA treatment of scleromyxoedema. Br J Dermatol 110:347, 1984
28. Blum M et al: Scleromyxedema: A case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine 87:10, 2008
29. Lacy MQ et al: Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. Arch Dermatol 141:1277, 2005
30. Donato ML et al: Scleromyxedema: Role of high-dose
melphalan with autologous stem cell transplantation.
Blood 107:463, 2006